3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
28
Gynecologic
22
Other solid neoplasm
14
Tumor-Agnostic
13
Genitourinary
12
Gastrointestinal
11
Thoracic
7
Head & Neck
5
Sarcoma
4
Lymphoid
4
Classical hematology
3
NET
2
Endocrine
2
Dermatologic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Thymoma
1
Mesothelioma
1
Interventions
Everolimus
15
Magnetic Resonance Spectroscopy
8
lutetium Lu 177 dotatate
7
pasireotide
5
gallium Ga 68 dotatate
5
Cisplatin
5
Specimen Handling
4
Positron Emission Tomography Computed Tomography
4
Nivolumab
4
Fluorodeoxyglucose F18
4
Carboplatin
4
Temozolomide
3
Paclitaxel
3
Octreotide
3
Lutetium-177
3
Ga(III)-DOTATOC
3
Etoposide
3
(177)Lu-DOTA-EB-TATE
3
vandetanib
2
pembrolizumab
2
olaparib
2
fluorodopa F 18
2
dabrafenib
2
copper dotatate CU-64
2
cemiplimab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Trastuzumab
2
Radiotherapy
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
olaparib
×
Endocrine
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled
NCT05870423
2025-06-05
PRRT-PARPi
Erasmus Medical Center
Phase 1
Recruiting
24 enrolled